Open-Label Extension Study to Pioneer Study 6058-SCD-101
Public ClinicalTrials.gov record NCT07401823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of Pociredir in Participants With Sickle Cell Disease (SCD) Who Have Participated in a Pociredir Study
Study identification
- NCT ID
- NCT07401823
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- Pociredir Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2026
- Primary completion
- Feb 3, 2030
- Completion
- Jul 4, 2030
- Last update posted
- Apr 13, 2026
2026 – 2030
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| Our Lady of the Lake Hospital | Baton Rouge | Louisiana | 70808 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Queens Hospital Cancer Center | Jamaica | New York | 11432 | — |
| Jacobi Medical Center | The Bronx | New York | 10461 | — |
| University of Texas Houston | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07401823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07401823 live on ClinicalTrials.gov.